Ascidian Therapeutics, a Boston, MA-based biotechnology company focused on treating human diseases by rewriting RNA, raised $40m in Series A extension funding.
The funds were committed by Apple Tree Partners (ATP).
The company intends to use the funds to advance its lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company’s pipeline.
Ascidian designs RNA editors to replace multiple mutated exons simultaneously. Using this platform, Ascidian can edit genes too large to package in viral vectors and genes with high mutational variance, thereby addressing underlying causes of complicated genetic diseases that are beyond the reach of current gene therapy and base editing approaches. Because Ascidian’s technique does not introduce exogenous enzymes, the risk of adverse immune reactions is reduced. And because it does not modify DNA, the risk of off-target effects is decreased.
The company anticipates submitting an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead program in ABCA4 retinopathies in early 2024. Beyond its lead program, Ascidian is advancing programs with first-in-class potential in neurological and neuromuscular disorders.
The company also announced that its founding CEO Michael Ehlers, M.D., Ph.D., will return as interim President and Chief Executive Officer, effective immediately. Dr. Ehlers, who also chairs Ascidian’s Board of Directors and serves as Chief Scientific Officer at ATP as well as a venture partner at the firm, succeeds Romesh Subramanian, Ph.D., who is departing Ascidian.
Ascidian Therapeutics, a Boston, MA-based biotechnology company focused on treating human diseases by rewriting RNA, raised $40m in Series A extension funding. Best wishes to everyone in the group. This will be a huge accomplishment for them in the future.Shishir Gupta, The Founder & CEO of StartupLanes
About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.
Startups looking for funding may apply through StartupLanes Funding Application.
Angel Investors Register Free to explore exciting startup investment opportunities.